BMS-191095_product_DataBase

Bioactivity

BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels[1][2][3].

Invitro

BMS-191095 (50 μmol/L) 诱导 SD 大鼠血管平滑肌细胞 (VSM) 线粒体去极化[1]。BMS-191095 (10-100 μmol/L) 剂量依赖性地诱导内皮剥脱脑动脉血管舒张[1]。BMS-191095 (50 μmol/L) 增加了细胞钙火花的频率[1]。BMS-191095 (0-1500 μM) 抑制胶原蛋白和凝血酶诱导的人血小板聚集，IC50 分别为 63.9 和 104.8 μM [2]。

In Vivo

BMS-191095 (2.5 或 25 μg；脑室内灌注，缺血诱导前 30 分钟/60 分钟/24 小时，1次) 可减轻短暂性局灶性脑缺血对大鼠神经元的损伤[3]。 Animal Model:

Name

BMS-191095

CAS

166095-21-2

Formula

C22H21ClN4O2

Molar Mass

408.88

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Katakam PV, et al. Diversity of mitochondria-dependent dilator mechanisms in vascular smooth muscle of cerebral arteries from normal and insulin-resistant rats. Am J Physiol Heart Circ Physiol. 2014 Aug 15;307(4):H493-503. [2]. Cho MR, et al. BMS-191095, a cardioselective mitochondrial K(ATP) opener, inhibits human platelet aggregation by opening mitochondrial K(ATP) channels. Arch Pharm Res. 2005 Jan;28(1):61-7. [3]. Mayanagi K, et al. The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2007 Feb;27(2):348-55.

PeptideDB

BMS-191095

CAS: 166095-21-2 F: C22H21ClN4O2 W: 408.88